Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 943-350-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Justification of read-across: Both chemicals are of comparable structures and can be characterized as esters of polyglycerol and fatty acids and undgo the same metabolism (Refer to Read Across Justification presented in Section 13). Justification of reliability of 2: scientifically well-performed study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: CARCINOGENIC RISKS IN FOOD ADDITIVES AND PESTICIDES (1960), Ministry of Health, UK
- Deviations:
- not specified
- GLP compliance:
- no
- Remarks:
- Studies were performed prior to implementation of GLP
- Limit test:
- no
Test material
- Reference substance name:
- Polyglycerol polyricinoleate
- IUPAC Name:
- Polyglycerol polyricinoleate
- Reference substance name:
- PGPR
- IUPAC Name:
- PGPR
- Reference substance name:
- 29894-35-7
- EC Number:
- 608-428-5
- Cas Number:
- 29894-35-7
- IUPAC Name:
- 29894-35-7
- Test material form:
- liquid: viscous
- Details on test material:
- PGPR is prepared by the esterification of condensed castor oil fatty acids (primarily ricinoleic acid)
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- other: rat and mouse
- Strain:
- other: rat: Wistar; mouse: C57BL
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Unilever Colworth Laboratory, Sharnbrook, Bedford, UK
- Age at study initiation: 32-46 days (rat); 6-8 weeks (mouse)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- rat study: 2-year
mouse study: 80-week - Frequency of treatment:
- feed; continuously
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0 and 5% (w/w, in diet)
Basis:
nominal in diet
- No. of animals per sex per dose:
- rat study: 30/sex/group
mouse study: 25/sex/group - Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale:
Rat study: The single dose level used for this study was chosen by comparing the likely human intake and the no-effect levels found in earlier chronic studies. Dosage levels for carcinogenicity studies should include a dose that is as high as can be administered without reducing the lifespan of the test animals. Previous studies showed no toxicity in rats fed 9% PGPR in diet for 45 wk. When testing food additives it is recognized that addition to the diet of levels above 5% can disturb the nutritional balance of the diet.
Mouse study: A single dose level was chosen for this study by comparing the likely human intake and the no-effect levels found in earlier subchronic and chronic rat feeding studies. PGPR was added to a semipurified diet at a level of 5% (by weight) by substituting part of the groundnut oil fed to control animals.
- Rationale for animal assignment (if not random): random - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- Rat Study:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- three times weekly and evaluated as a weekly amount.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood and how many animals: after 80 wk from four rats of each sex fed PGPR or the control diet, and on all surviving animals at study termination
- Anaesthetic used for blood collection: Yes
- Animals fasted: No data
- Parameters: erythrocyte and leucocyte counts, haemoglobin concentrations and value, red cell fragility and prothrombin time.
CLINICAL CHEMISTRY: No data
URINALYSIS: yes
NEUROBEHAVIOURAL EXAMINATION: No
Mouse Study:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- twice weekly and evaluated as a weekly amount.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood and how many animals: all surviving animals at study termination
- Anaesthetic used for blood collection: Yes
- Animals fasted: No data
- Parameters: erythrocyte and leucocyte counts and haemoglobin concentrations
CLINICAL CHEMISTRY: No data
URINALYSIS: yes
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- Rat Study:
GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Each animal was subjected to gross examination at autopsy. The following organs were weighed and the organ/body weight ratios determined: adrenals, heart, kidney, spleen, liver, testes, thyroid and pituitary. These organs, together with the lung, ovary, uterus, thymus, stomach, intestine, caecum, bladder, lymph nodes, skin, mammary gland, tongue and any macroscopic abnormality were removed, fixed and processed for histological examination.
Mouse Study:
GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Each animal was subjected to gross examination at autopsy (at test termination and for those animals dying during the test). The following organs were weighed: heart, kidney, liver and testes. These organs, together with lung, spleen, adrenals, skin, stomach, intestine, thyroid, thymus, mammary gland and lymph nodes, together with any macroscopic abnormality were removed, fixed and processed for histological examination. - Other examinations:
- In rat study, Liver function was examined after 84 and 103 week using the bromosulfothalein excretion test. Kidneyfunction was assessed at the same times by measuring urine concentration.
- Statistics:
- All records were examined separately for each sex by analysis of variance to assess the significance of any inter-group differences. Organ weightswere also analysed if justified by an analysis of covariance on final body weight.
In the analysis of variance, the F-ratio test was used to test whether the treatments differed. Student's t-tests were then used to compare every treatment mean individually against the control.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- ORGAN WEIGHTS
Rat study:
Organ weight measurements showed that kidneys from male and female rats and livers from female (but not male) rats fed PGPR were heavier than those fed the control diet.
Mouse study:
Organ weight measurements revealed that livers and kidneys from female mice fed PGPR were heavier than those from mice fed the control purified diet.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Remarks:
- no NOAEL identified
Target system / organ toxicity
- Key result
- Critical effects observed:
- not specified
Any other information on results incl. tables
Rats in both treatment and control groups occasionally showed clinical signs of respiratory disease, which in some cases was accompanied by loss of body weight and reduced food consumption. The incidence of respiratory disease was most evident from wk 50 onwards. Bronchiectasis and emphysema were the main cause of death among animals in both test and control groups. The incidence of respiratory disease was comparable between treatment and control groups.
Mean weights of liver and kidney of rats and mice.
Species | Organ | Mean organ weights (g) | |||
Males | Females | ||||
PGPR diet | Purified diet (control) | PGPR diet | Purified diet (control) | ||
Rats | Liver | 12.18 | 11.45 | 9.15 * | 8.67 |
Kidney | 3.59 * | 3.19 | 2.52 * | 2.37 | |
Mice | Liver | 2.81 | 2.54 | 3.55 * | 2.26 |
Kidney | 0.70 | 0.68 | 0.66 * | 0.53 |
* significantly different from control (P=0.05)
Applicant's summary and conclusion
- Conclusions:
- The treatment of 5% target chemical in the diet (approx. 2500 mg/kg bw/day) is not considered likely to induce adverse effects in rats and mice.
- Executive summary:
The repeated dose toxicity of the target substance was assessed based on the analogue approach using PGRP as a read-across supporting substance.
The long-term toxicity potential of PGPR was evaluated in rats and mice. Groups of 60 male and 60 female rats were given purified diets containing 5% of either PGPR or groundnut oil for 2 years. Groups of 25 male and 25 female mice were given purified diets containing 5% of either PGPR or groundnut oil for 80 weeks. No carcinogenic effect of PGPR was observed. In addition, dietary PGPR had no adverse effect on growth, food consumption, longevity and haematology. Organ weight analysis revealed an increase in liver and kidney weight in both male and female rats and female mice. Histological analysis of tissues revealed no treatment related adverse effects. Based on the results, it was concluded that treatment of 5% test item in the diet (approx. 2500 mg/kg bw/day) did not induce adverse effects in rats and mice. Likewise, treatment with the target chemical of the same level is not considered likely to induce adverse effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.